Why the study?
Does desmopressin improve coagulation and fibrinolysis profiles in patients undergoing total hip replacement?
Does desmopressin improve coagulation and fibrinolysis profiles in patients undergoing total hip replacement?
Desmopressin improves coagulation and fibrinolysis parameters in patients undergoing total hip replacement, potentially reducing the risks of both hemorrhage and thromboembolism.
May warrant desmopressin consideration in hip replacement to balance bleeding and thrombosis risks; extends RCT evidence on coagulation parameters.
Twelve patients undergoing total hip replacement, with regional anaesthesia and with dextran infusion for plasma expansion and thromboprophylaxis, were given the vasopressin analogue desmopressin (DDAVP) or placebo in a randomized, double-blind prospective study. In controls (n = 6) we found a prolongation of the bleeding time, low factor VIII (FVIII) and von Willebrand factor (vWF) and a decrease in antithrombin III to levels known to be at risk for venous thrombosis. Desmopressin shortened postoperative bleeding time, gave an early FVIII/vWF complex increase, prevented antithrombin III from falling to critically low values and appeared to activate the fibrinolytic system, both by tPA increase and PAI-1 decrease. Thus in the controls we found changes in both coagulation and fibrinolysis indicating a haemorrhagic diathesis as well as a risk for thromboembolism. Desmopressin induced factor changes that possibly reduce both risks.
No takes yet. Share an insight, caveat, or question.
Flordal et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: